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Background: Previous reports identified proteins associated with ‘apoptosis’ following
cross-linking PrPC with motif-specific anti-PrP antibodies in vivo and in vitro. The
molecular mechanisms underlying this IgG-mediated neurotoxicity and the role of the
activated proteins in the apoptotic pathways leading to neuronal death has not been
properly defined. Previous reports implicated a number of proteins, including
apolipoprotein E, cytoplasmic phospholipase A2, prostaglandin and calpain with anti-
PrP antibody-mediated ‘apoptosis’, however, these proteins are also known to play an
important role in allergy. In this study, we investigated whether cross-linking PrPC with
anti-PrP antibodies stimulates a neuronal allergenic response.
Methods: Initially, we predicted the allergenicity of the epitope sequences associated with
‘neurotoxic’ anti-PrP antibodies using allergenicity prediction servers. We then investigated
whether anti-PrP antibody treatment of mouse primary neurons (MPN), neuroblastoma cells
(N2a) and microglia (N11) cell lines lead to a neuronal allergenic response.
Results: In-Silico studies showed that both tail- and globular-epitopes were allergenic.
Specifically, binding regions that contain epitopes for previously reported ‘neurotoxic’
antibodies such as ICSM18 (146-159), ICSM35 (91-110), POM 1 (138-147) and POM 3
(95-100) lead to activation of allergenic related proteins. Following direct application of anti-
PrPC antibodies on N2a cells, we identified 4 neuronal allergenic-related proteins when
compared with untreated cells. Furthermore, we identified 8 neuronal allergenic-related
proteins following treatment of N11 cells with anti-PrPC antibodies prior to co-culture with
N2a cells when compared with untreated cells. Antibody treatment of MPN or MPN
co-cultured with antibody-treated N11 led to identifying 10 and 7 allergenic-related
proteins when compared with untreated cells. However, comparison with 3F4 antibodyorg July 2021 | Volume 12 | Article 6390081
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showed that the allergenic effects triggered by the anti-PrP antibodies were more potent
when antibody-treated microglia were co-cultured with the neuroblastoma cell line. Finally,
co-culture of N2a or MPN with N11-treated with anti-PrP antibodies resulted in significant
accumulation of NO and IL6 but not TNF-a in the cell culture media supernatant.
Conclusions: This study showed for the first time that anti-PrP antibody binding to PrPC
triggers a neuronal hypersensitivity response and highlights the important role of microglia
in triggering an IgG-mediated neuronal hypersensitivity response. Moreover, this study
provides an important impetus for including allergenic assessment of therapeutic
antibodies for neurodegenerative disorders to derive safe and targeted biotherapeutics.Keywords: anti-PrP antibodies, cellular prion protein, neurotoxicity, allergenicity, mouse primary neurons,
neuroblastoma cell line, microglia cell lineINTRODUCTION
Prion diseases or transmissible spongiform encephalopathies
(TSE) are invariably fatal diseases characterized by loss of
motor control, dementia and paralysis (1, 2). These disorders
are caused by the conversion of a transmembrane cellular prion
protein (PrPC) into a misfolded form (PrPSc) (3, 4). PrPC is a
soluble protein rich in alpha helical content while PrPSc is rich in
b-pleated sheets and characterised by its insolubility in
detergents and partial resistance to proteases (4–7). The
function of PrPC has not been completely elucidated but due
its conserved nature in a wide range of species, it is believed to
play key and vital roles in maintaining cell homeostasis.
However, PrPC was implicated in cell activation, proliferation
and differentiation (8–10), copper binding (11), synaptic
plasticity and signal transduction (12–15). Prion diseases
immunotherapeutics that directly target PrPSc elimination and
transient inhibition of PrPC have been efficacious in rodent
models (16–20). However, several reports highlighted potential
side-effects caused by anti-PrPC antibody treatment in vitro and
in vivo (12, 15, 21–25). Of note, the antibody-mediated
‘neurotoxic’ effects reported previously were made on the basis
of microscopic assessments following TUNEL and/or standard
histological staining but have not been characterized at a
molecular level (23, 24, 26), with the exception of reports by
Tayebi et al, Sonati et al. and Goniotaki et al. that confirmed the
association of apolipoprotein E (APOE), cytoplasmic
phospholipase A2 (cPLA2), prostaglandin (PG), calpain
(CAPN) and group-I metabotropic glutamate receptors
(mGluR1 and mGluR5) with anti-PrP mediated ‘neurotoxicity’
(21, 27, 28). In fact, these proteins are known to play a key role in
allergic reactions, and most were identified as human allergy-
related proteins by the AllerGAtlas database. For instance, levels
of APOE in the bronchoalveolar fluid derived from patients with
hypersensitivity pneumonitis were shown to be significantly
high and APOE was suggested to play an important role in
this allergic disease (29). Moreover, impaired delayed type
hypersensitivity responses were observed in APOE-null mice,
demonstrating the important role of APOE in regulatingorg 2allergy (30). The role of cPLA2 in allergic response was
characterized (31). Uozumi and colleagues showed that cPLA2-
deficient mice displayed marked decrease in the synthesis of
eicosanoids (including PG) and platelet activating factor and that
the anaphylactic responses were significantly affected. Moreover,
cPLA2 was also shown to be essential for fast eicosanoid
generation (including PG) by providing arachidonic acid (32).
PGs are synthesized by the cyclooxygenase (COX) enzymes in
the arachidonic acid metabolic pathway and have been shown to
play an important role in hypersensitivity (33). The neuron-
expressed mGluR7 was shown to regulate histamine and ablation
of mGluR7 in mice led to anaphylaxis (34). Of importance,
mGluR7-interactors; mGluR1 and mGluR5 were shown to form
complexes with PrPC and their pharmacological inhibition
cancelled the ‘neurotoxic’ effects caused by anti-PrP antibodies
(28). Of interest, the anti-histaminic drug astemizole, a second
generation H1-receptor antagonist, was shown to extend the
survival of mice infected with prions (35), suggesting a
connection between PrP and histamine.
Microglia activation is an important neuropathological
feature associated with neurodegenerative disorders, including
prion diseases (36–38). It was previously reported that the
cytotoxic effects triggered by a putative toxic PrP peptide were
intimately linked to microglia activation (36, 39). Moreover, a
report by Lefebvre-Roque et al. demonstrated that a 2-week
intraventricular infusion of a full length anti-PrPC antibody or
with its F(ab’)2 and Fab fragment derivative to wild-type and
prion-infected mice initiated at the beginning of prion
neuroinvasion led to microglial recruitment/activation (25).
Interestingly, the authors show that microglial activation
associated with neuronal death was only observed after
injection of anti−PrP antibodies and did not seem to be related
to prion infection.
In this study, we aimed to verify whether direct treatment of
neurons with anti-PrP antibodies or following co-culture with
anti-PrP antibody-treated microglia leads to a neuronal
hypersensitive response. In order to investigate the molecular
mechanisms underlying antibody-induced toxicity, mass
spectrometry analysis was performed to identify allergenicJuly 2021 | Volume 12 | Article 639008
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Mediated Neuronal Hypersensitivity post-antibody treatment.
Here, we used a set of anti-PrP antibodies, including ICSM
(40), SAF (41, 42), and POM antibodies (43) with binding
specificity for epitopes located on the globular domain (GD) or
flexible tail (FT) of PrPC. We show that direct application of anti-
PrP antibodies (DAT) on N2a induces a neuronal allergenic
reaction by activating 4 allergenic-related proteins. Co-culture of
N2a with antibody treated N11 (DMT) led to a more extensive
alteration of the proteome and identified 8 allergenic-related
proteins. Furthermore, DAT and DMT of mouse primary
neurons (MPN) revealed 10 and 7 allergenic-related proteins
respectively when compared with untreated cells; and 5 and 4
allergenic-related proteins when compared with treatment with a
hamster/human specific anti-PrP 3F4 antibody. Of importance,
we show that DMT with some of these anti-PrP antibodies lead
to a substantial release of proinflammatory cytokine Interleukin
6 (IL6) but not Tumour Necrosis Factor alpha (TNF-a)
confirming a possible role of anti-PrP antibodies in triggering
a type 2-like hypersensitive reaction (44). Finally, we show that
FceR1a was activated following treatment with anti-PrP
antibodies. This study demonstrates and for the first time that
cross-linking PrPC with anti-PrP antibodies leads to a neuronal
allergic reaction and also highlights the crucial role played by
microglia in this IgG-Mediated Neuronal Type-2 like
Hypersensitive reaction.METHODS
The overall methods of the in-silico study, in vitro experimental setup,
western blotting, immunofluorescence study and liquid-
chromatography mass-spectrophotometry (LC-MS) analysis are
illustrated in Figure 1. Methods related to the predictions of the 3-
dimensional structure of the human PrPC; of linear and
conformational B cell epitopes; and of the toxicity and allergenicity
of the linear B cell epitopes are described in extended methods.
Treatment of Neurons and Microglia Cell
Line With Anti-PrP Antibodies
We used a mouse neuroblastoma (N2a) (American Type Culture
Collection, ATCC, USA) (45), mouse primary neurons (MPN)
derived from eight week-old wild-type (WT) mice (C57BL/6 x
SV129 background) harvested from the brain’s sub ventricular
zone (SVZ) as described (46), and a mouse microglia (N11) (47)
cell line to investigate the effects of anti-PrP antibodies. The N2a
cells were used to assess hypersensitivity following direct
application of anti-PrP antibodies (DAT). The N11 cells,
initially treated with anti-PrP antibodies, were used to assess
their effects on N2a or MPNs following direct co-culture (DMT)
or after separating the antibody treated N11 and N2a cells by a
tissue culture insert (IMT).
Direct Antibody Treatment (DAT)
N2a cells were plated on 24 tissue culture well plates (Falcon,
country) at 200,000 cells/well for 48 hours in tissue cultureFrontiers in Immunology | www.frontiersin.org 3medium [Dulbecco’s Modified Eagle Medium (DMEM)
(Thermo Fisher Scientific, Australia), 10% fetal bovine serum
(FBS) (Gibco, Fisher Scientific, Australia), and 1% Penicillin-
streptomycin (Sigma, USA)] at 37°C in 5% CO2 until optimum
growth and adhesion to the surface of the plates were observed.
The medium was changed daily. After 48 hours, 3mg of different
anti-PrP antibodies, including ICSM18 (40), ICSM35 (40),
POM1 (43), POM2 (43), POM3 (43), SAF32 (42), or SAF70
(41) were added daily to the N2a cultures for 3 days. The cells
were then removed from the plates and centrifuged at 800 rpm
for 5 minutes. The cells were lysed with NP-40 lysis buffer
(150mM NaCl, 1.0% Nonidet P-40 and Triton X-100, 50 mM
Tris-Cl, adjust PH to 7.4) with addition of AEBSF protease
inhibitor (Sigma, USA) and stored at −80°C until further use.
Undifferentiated WT MPN were plated in 24 well plate at
50,000 cells/well in NeuroCult™ Differentiation kit (Stem Cell
Technologies, Canada) and incubated at 37°C in 5% CO2 for 7
days. The cells were then treated daily with 1mg of ICSM18,
ICSM35 (40) or 3F4 (Sigma-Aldrich, Australia) for 3 days. Cells
were then trypsin-removed from the plates, centrifuged at 800
rpm for 5 minutes and lysed with NP-40 lysis buffer (150mM
NaCl, 1.0% Nonidet P-40 and Triton X-100, 50 mM Tris-Cl,
adjust PH to 7.4) with addition of AEBSF protease inhibitor
(Sigma, USA) and stored at −80°C until further use.
Direct Microglia Treatment (DMT)
For co-culture with N2a cells, the N11 cells were plated and
cultured on a Petri dish at 200,000 cells/well for 48 hours in
culture medium and incubated at 37°C in 5% CO2. N11 cells
were then treated with 3mg of different anti-PrP antibodies as
above daily for 3 days. The antibody treated N11 cells were
centrifuged at 800 rpm for 5 minutes before co-culturing with
confluent N2a cells for 3 days. Finally, the N2a/antibody-treated
N11 co-culture was centrifuged at 800 rpm for 5 minutes and the
pellet was lysed with NP-40 lysis buffer with addition of AEBSF
protease inhibitor then stored at −80°C until further use. The
supernatants were snap frozen in liquid nitrogen and stored at
−80°C until further use. In another experiment, the antibody-
treated N11 cells were centrifuged at 800 rpm for 5 minutes and
the pellet was lysed with NP-40 lysis buffer with addition of
AEBSF protease inhibitor then stored at −80°C until further use.
The supernatants were snap frozen in liquid nitrogen and stored
at −80°C until further use.
For co-culture with MPN, the N11 cells were plated and
cultured on a 24 well plate at 50,000 cells/well for 24 hours in
culture medium (DMEM medium, 10% FBS, and 1% Penicillin-
streptomycin) and incubated at 37°C in 5% CO2. The cells were
then treated with 1mg of ICSM18, ICSM35 or 3F4 antibody as
above. The antibody treated N11 cells were centrifuged at
800 rpm for 5 minutes before co-culturing with confluent
MPN for 3 days. Finally, the WT MPN and antibody treated
N11 co-culture was centrifuged at 800 rpm for 5 minutes and the
pellet was lysed with NP-40 lysis buffer with addition of AEBSF
protease inhibitor then stored at −80°C until further use. The
supernatants were snap frozen in liquid nitrogen and stored
at −80°C until further use.July 2021 | Volume 12 | Article 639008
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In order to verify whether the potential allergenic effect is caused
by molecules released from N11 cells following treatment with
anti-PrP antibodies, the N11 cells were plated and cultured on
tissue culture inserts (Nunc™ Polycarbonate Cell Culture
Inserts, 0.4-micron pore size) in 24 well plate at 200,000 cells/
well for 48 hours. The N11 cells were treated daily with 3mg of
different anti-PrP antibodies as above. The tissue culture inserts
containing antibody-treated N11cells were transferred to 24 well
tissue culture plate containing confluent N2a cells and left for 3
days. Finally, the N2a cells were removed from the wells and
centrifuged at 800 rpm for 5 minutes and lysed with NP-40 lysisFrontiers in Immunology | www.frontiersin.org 4buffer and AEBSF protease inhibitor before storing at −80°C
until further use.
Sample Preparation for Liquid
Chromatography-Mass Spectrometry
In-Solution Trypsin Digestion
The cell lysates prepared above were used for Liquid
Chromatography-Mass Spectrometry (LC-MS) sample
preparation. For in-solution trypsin digestion, 100ml of protein
sample (300 µg/mL cell lines or 170 µg/ml MPN) was
concentrated using Rotational Vacuum Concentrator (Martin
Christ Gefriertrocknungsanlagen GmbH, Germany). 6 µL DTTFIGURE 1 | Overall workflow of the in silico and in vitro study for the identification of allergenic proteins following antibody treatment and LC-MS analysis.July 2021 | Volume 12 | Article 639008
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in Tris buffer, pH 7.8) was then added and themixture was vortexed
before addition of 30 µL of 6MUrea into the sample then incubated
for 1h at room temperature. 6 mL iodoacetamide (Sigma-Aldrich,
Australia) alkylating reagent (200 mM iodoacetamide in Tris buffer,
pH 7.8) was then added, the sample mixture vortexed then followed
by incubation for 1h at room temperature. The mixture was topped
up with 225 µL of distilled water before adding 5 µL of trypsin
(Promega Corporation, USA) solution and incubated overnight at
37°C. Finally, the reaction was stopped, and the pH of the solution
adjusted to <6 with concentrated acetic acid. After trypsin digestion,
the solution was purified using Solid Phase Extraction (SPE - Oasis
HLB 1 cc Vac Cartridge, 30 mg) vacuummanifold (Waters Milford,
Massachusetts, USA) then reconstituted in 15µL 0.1% formic acid,
vortexed and kept for 30 minutes at 25°C. The solution was then
vortexed and sonicated for 3 minutes then centrifuged at 14,000
rpm for 10 minutes before transferring into labelled glass vials.
In-Gel Trypsin Digestion
Cell lysates derived from ICSM35 or 3F4 antibody-treated MPN
were run in a 12% SDS-PAGE gel (Bio-Rad, CA, USA) as above.
Silver staining (ThermoFisher Scientific, Australia) was
performed following the manufacturer’s instructions. Band
were then cut out and used for in-gel trypsin digestion for final
LC-MS analysis. Initially, 200 mL wash solution (50%
acetonitrile, 50 mM ammonium bicarbonate) was added to the
sample following continuous vortex for 10 minutes at room
temperature. The solution was removed and repeated two times.
200 mL of acetonitrile was added to the gel, vortexed briefly and
incubated at room temperature for 5 minutes. Acetonitrile was
removed and residual amount was evaporated with a heated
vacuum centrifugal concentrator for 5 minutes. 100 mL of the
freshly prepared DTT solution (10 mM DTT in 50 mM
ammonium bicarbonate) was added to the dried gel and
incubated at 55°C for 1 hour. 100 mL of freshly prepared
iodoacetamide solution (55 mM iodoacetamide in 50 mM
ammonium bicarbonate) was then added to the gel then mixed
by brief vertexing and incubated in the dark at room temperature
for 45 minutes. 200 mL of wash solution was added to the sample
following continuous vertexing for 10 minutes at room
temperature. The wash solution was removed and repeated two
times. 200 mL of acetonitrile was added to the gel, vortexed briefly
and incubated at room temperature for 5 minutes. Acetonitrile
was removed and discarded, and the residual acetonitrile was
evaporated with a heated vacuum centrifugal concentrator for 5
minutes. 15 mL of 20 ng/mL trypsin solution (Promega
Corporation, USA) (in 50 mM ammonium bicarbonate) was
added to the dried gel core following 1 hour incubation at 30°C
for rehydrating the gel. Sufficient amount of digestion buffer (50
mM ammonium bicarbonate/10% acetonitrile) was added to the
gel and incubated at 37°C overnight. 50 mL of ultrapure (≥18
MW) H2O was added to the in-gel digestion mixture following
continuous vertexing for 10 minutes at room temperature. The
supernatant was removed and collected in a fresh, non-stick
micro centrifuge tube prior to adding 50 mL of 50% acetonitrile/
5% formic acid (v/v) and incubated the tube for 60 minutes at
room temperature with frequent vortexing. The solution wasFrontiers in Immunology | www.frontiersin.org 5collected after spinning the tube briefly in a micro centrifuge.
Finally, the volume of the pooled solution was concentrated
using a centrifugal concentrator at room temperature until the
appropriate volume (~20 mL) is reached. The samples were then
transferred into glass vial and ready for LS-MS analysis.
Liquid Chromatography-Mass
Spectrometry Analysis
The samples prepared above were carefully placed in aWaters Total
Recovery chromatography sample vials for analysis. System specific
cleaning protocol was run before loading the sample to avoid
contamination in the system. LC-MS was performed using a
Waters nanoAcquity UPLC equipped with a Waters nanoEase M/
Z Peptide BEH C18 Column, 130Å, 1.7 µm 75 um x 100 mm,
thermostatted to 40°C (Waters Corporation, USA). Briefly, solvent
A consisted of ultrapure water (Milli-Q) plus 0.1% formic acid and
solvent B consisted of LC-MS grade acetonitrile (Burdick and
Jackson) plus 0.1% formic acid. Samples were injected onto a
trapping column (Waters nanoEase M/Z Symmetry C18 Trap
Column, 100A, 5 µm, 180 µm x 20mm) at 5 uL/min at 99%
Solvent A for 3 min before being eluted on the Analytical Column
with a flowrate of 0.30 uL/min. An initial solvent composition of 1%
B was ramped to 85% B over 50 minutes. Injections of 1 mL were
made from sample solutions stored at 4°C.
Mass spectrometry was performed using aWaters SYNAPTG2-
Si (HDMS) spectrometer fitted with a nano electrospray ionization
source and operating in positive ion mode. Mass accuracy
was maintained by infusing at 0.5 mL/min a lock spray solution of
1 pg/mL leucine encephalin in 50% aqueous acetonitrile, plus 0.1%
formic acid, calibrated against a sodium iodide solution. The
capillary voltage was maintained at 3 kV, cone voltage at 30 V,
source offset at 30 V, ion block temperature 80°C, gas (N2) flows:
purge gas 20 L/hr., cone gas 20 L/hr. MassLynx Mass Spectrometry
Software (Waters Corporation, USA) was used to process the data.
Each sample was run for three times in the LC-MS system and
finally the collected data were run against the mouse proteome
using Uniprot database and analysed using Progenesis QI software
(Waters Corporation, USA).
Identification of the Allergy Related Genes
The final dataset from LC-MS was checked to find out whether
there is any allergy related genes or not in our identified gene list.
We used AllerGAtlas 1.0 (http://biokb.ncpsb.org/AlleRGatlas/),
a human allergy-related genes database which has been
developed based on the 1195 well-annotated human allergy-
related genes, determined by text-mining and manual curation
(48). The objectives of developing this AllerGAtlas database was
to look on the pathogenesis and epidemiology of individual
cases, novel diagnostic and prognostic biomarker, individual
treatment responses and precision medicine (48).
Western Blot Analysis
Cell lysates derived from antibody-treated cell lines and MPN
was mixed with an equal volume of Laemmli buffer (Bio-Rad,
CA, USA). The solution was vortexed then heated for 5 min to
95°C. The solution was left to cool down before loading the
sample into 12% SDS-PAGE gel (Bio-Rad, CA, USA) and run atJuly 2021 | Volume 12 | Article 639008
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(Bio-Rad, CA, USA). Following transfer at 18V for 2h 30 min in
transfer buffer (Bio-Rad, CA, USA), the membranes were blocked
using 2% bovine serum albumin (BSA) (Sigma-Aldrich, USA) or
5% skimmed milk followed by human TrueStain FCx™ blocker
(Biolegend, San Diego, USA) (5µl/blot). The blots were rinsed with
TBST and 0.5 µg/ml of primary antibody mouse anti-human
FcϵRIa (Biolegend, San Diego, USA) was added for overnight
incubation before washing with 0.1% TBST buffer. The secondary
antibody goat anti-mouse IgG (Fab specific) (1:80000) (Sigma-
Aldrich, USA) was then added for 1hour at room temperature. The
blot was washed using 0.1% TBST then visualized using the Clarity
Western ECL Substrate (Bio-Rad, CA, USA) in iBright™ CL1000
Imaging System (Thermo Fisher Scientific).
Nitric Oxide, TNFa and IL-6 assays
Nitric oxide (NO) production was measured in all antibody-
treated cells and N11 cells by Griess reaction. Cell supernatants
were collected and mixed with Griess reagent (1% sulfanilamide
in 5% phosphoric acid and 0.1% N-1-naphthylethylenediamine
dihydrochloride in Milli-Q water) for NO measurement in a
microplate which was monitored under 540 nm using a
microplate reader (BMG CLARIOstar, Victoria, Australia).
Supernatants derived from anti-PrP-treated cells were also
collected and analysed for IL-6 and TNF-a synthesis using
commercial ELISA kits (IL6: Biolegend, Australia; TNF:
Peprotech, Australia) according to the manufacturer’s instructions.
Statistical Analyses
Statistical analyses were assessed using GraphPad Prism 9 with
One-way ANNOVA followed by Tukey’s multiple comparisons
test method. The results were considered significant at p<0.05.RESULTS
Identification of Allergenic B Cell Epitopes
in the Three-Dimensional Structure of the
Human Major Prion Protein
Following modelling of the human major prion protein (huPrP)
3-dimensional structure (Figure S1), we predicted the linear B cellFrontiers in Immunology | www.frontiersin.org 6epitopes from the huPrP 3D structure and found 10 B cell linear
epitopes ranging from 4 to 26 amino acids long with a protrusion
index (PI) of 0.503 to 0.798 (Table 1) (49). The full-length huPrP
is divided into three major parts, including the flexible tail (FT)
region (23-123), which comprises the octa-peptide repeats (OR)
region (50-90) and the globular domain (GD) regions (124-230).
We found four epitopes (epitope L7: 24-49, epitope L9: 56-66 and
epitope L10: 76-86, epitope L2: 89-111) in the FT region, two of
them located in the OR region. The GD contained three epitopes
(epitope L4: 137-153, epitope L3: 167-174 and epitope L6: 189-
204). On the contrary, the short epitope 1-4 (epitope L8) is located
in the N-terminal region (signal peptide region) and
comparatively two longer epitopes L1:222-238 (both in GD and
non-structured region) and L5:245-253 (non-structured region)
are located in the C-terminal region of the full length huPrP
(Table 1). The position of the B cell linear epitopes on the protein
structure are illustrated in (Figures 2A, B). We also predicted 9 B
cell conformational epitopes, shown in Table 2. The length of the
B cell conformational epitopes ranged between 4 and 36 amino
acid residues. The protrusion index value for the B cell
conformational epitopes ranged between 0.55 and 0.883.
TheBcell linear epitopeL2overlappedwithBcell conformational
epitopes C2 and C9 (Tables 1 and 2). Further, linear epitope L4 also
overlappedwith conformational epitopeC4 (Tables 1 and 2). On the
other hand, rest of the other linear epitopes L1 overlapped with both
C1 and C6; L3 overlapped with C5; L5 overlapped with C7; L6
overlappedwithC4;L7overlappedwithbothC3andC8; andbothL9
and L10 overlapped with C9 (Figures 2C, D).
In the in silico analysis, the prediction of the toxicity for each
linear epitope was achieved with ToxinPred server (http://crdd.
osdd.net/raghava/toxinpred/) using Support Vector Machine
(SVM) and Quantitative Matrix (QM) method (50). The SVM
method did not identify ‘toxic’ B cell linear epitopes from 3D
structure however, the QM method identified epitopes L2 (89-
111), L4 (137-153), L7 (24-49), L9 (56-66), and L10 (76-86) as
being toxic. Of note, L2 and L4 epitope contain the binding
sequences for the ‘neurotoxic ’ anti-PrP antibodies
ICSM35/POM3 antibodies (40, 43) and ICSM18/POM1
antibodies (40, 43), respectively. Interestingly, epitopes L9 (56-
66) and L10 (76-86) are located in the octa-repeat region of the
huPrP protein that contains the binding sequences for SAF 32TABLE 1 | Linear B cell epitopes and their toxicity and allergenicity from the three-dimensional structure of the human major prion protein.
Epitope No. Position Peptide Number of Residues Score Allergenicity Overall
AllergenFP AllerTop 2.0
L1 222-238 SQAYYQRGSSMVLFSSP 17 0.798 Non-allergenic Non-allergenic Non-allergenic
L2 89-111 WGQGGGTHSQWNKPSKPKTNMKH 23 0.767 Non-allergenic Allergenic Allergenic
L3 167-174 DEYSNQNN 8 0.751 Allergenic Non-allergenic Allergenic
L4 137-153 PIIHFGSDYEDRYYREN 17 0.737 Allergenic Non-allergenic Allergenic
L5 245-253 SFLIFLIVG 9 0.701 Non-allergenic Non-allergenic Non-allergenic
L6 189-204 VTTTTKGENFTETDVK 16 0.685 Non-allergenic Non-allergenic Non-allergenic
L7 24-49 KRPKPGGWNTGGSRYPGQGSPGGNRY 26 0.676 Non-allergenic Non-allergenic Non-allergenic
L8 1-4 MANL 4 0.559 Allergenic Allergenic Allergenic
L9 56-66 GWGQPHGGGWG 11 0.541 Non-allergenic Allergenic Allergenic
L10 76-86 PHGGGWGQPHG 11 0.503 Non-allergenic Allergenic AllergenicJuly 2021 | Volume 12 | Article 639008
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DC
FIGURE 2 | Predicted linear and conformational B cell epitopes and their position in the human major prion protein structure. Here, the protein structures have
shown as cartoon structure and the linear and conformational B cell epitopes have shown as spheres on the protein structures. (A) Linear B cell epitopes where L1
(222-238), L2 (89-111), L3 (167-174), L4 (137-153), L5 (245-253), L6 (189-204), L7 (24-49), L8 (1-4), L9 (56-66), and L10 (76-86) representing different epitope
position. (B) all the linear B cell epitopes have been shown as spheres by different colours to see the overlaps of the identified linear B cell epitopes.
(C) Conformational B cell epitopes where C1(227-235), C2 (100-112), C3 (25-38), C4 (137-149, 151-153, 157, 189, 191-204), C5 (164, 168-174, 177), C6
(222-225), C7 (236-238, 242, 245-253), C8 (39-49), and C9 (55-67, 75-86, 89-99) representing different epitope position. (D) all the conformational B cell epitopes
have been shown as spheres by different colours to see the overlaps of the identified conformational B cell epitopes. Here, liner B cell epitope L1 was found in the
conformational B cell epitope position C1 and C6; C2 and C9 representing the linear epitope L2; C5 representing the linear epitope L3; C4 (two position where one
is in the left side and the other one is in the middle position of the structure) representing the linear epitope L4 and L6; C7 representing the linear epitope C5; C3 and






C1 Q227, R228, G229, S230, S231, M232, V233, L234, F235 9 0.883
C2 N100, K101, P102, S103, K104, P105, K106, T107, N108, M109, K110, H111, M112 13 0.811
C3 R25, P26, K27, P28, G29, G30, W31, N32, T33, G34, G35, S36, R37, Y38 14 0.747
C4 P137, I138, I139, H140, F141, G142, S143, D144, Y145, E146, D147, R148, Y149, R151, E152, N153, Y157, V189, T191, T192,
T193, K194, G195, E196, N197, F198, T199, E200, T201, D202, V203, K204
32 0.717
C5 R164, E168, Y169, S170, N171, Q172, N173, N174, H177 9 0.708
C6 S222, Q223, A224, Y225 4 0.708
C7 S236, S237, P238, L242, S245, F246, L247, I248, F249, L250, I251, V252, G253 13 0.669
C8 P39, G40, Q41, G42, S43, P44, G45, G46, N47, R48, Y49 11 0.579
C9 G55, G56, W57, G58, Q59, P60, H61, G62, G63, G64, W65, G66, Q67, Q75, P76, H77, G78, G79, G80, W81, G82, Q83, P84,
H85, G86, W89, G90, Q91, G92, G93, G94, T95, H96, S97, Q98, W99
36 0.55Frontiers in Immunology | www.frontiersin.org July 2021 | Volum7 e 12 | Article 639008
Adhikari et al. Anti-PrPC Antibody-Neuronal Hypersensitivity(59-89) (42) and POM2 (57-88) antibodies (43), respectively. We
also predicted the allergenicity for the B cell linear epitopes using
the AllergenFP (51) and AllerTop (52) allergenicity prediction
server. L3 (167-174), L4 (137-153), and L8 (1-4) were predicted
to be allergenic in AllergenFP, while AllerTop server identified
epitopes L2 (89-111), L8 (1-4), L9 (56-66), and L10 (76-86) as
allergenic. The allergenicity prediction results are shown in
Table 1. Three linear epitopes were shown to be non-toxic and
non-allergenic and included L1 (222-238) and L6 (189-204) on
the globular domain and L5 (245-253) located on the non-
structured region. We therefore investigated whether ICSM18,
ICSM35, POM1, POM2, POM3, SAF32, and SAF70 antibodies
trigger a neuronal allergenic reaction in vitro.
Anti-PrP Antibodies Treatment Leads to
Neuronal Type 2-Like Hypersensitivity
In Vitro
Treatment of N2a cells with ICSM18, ICSM35, POM1 and SAF70
led to the identification of 211 proteins (p <0.05) after LC-MS
analysis when compared with untreated N2a cells. Out of the 211
proteins, only differentially expressed proteins were considered
using maximum fold change ≥10, at least 2 identified unique
peptides and a confidence score ≥ 40. The stringent parameters
used here led to the identification of 26 proteins (Table S1). Of note,
the parameters used to identify proteins associated with anti-PrP
treatment are unusually high and would allow elimination of ‘false-
negatives’ post LC-MS analysis. The 26 proteins were then assessed
for allergenicity using AllergGAtlas database (http://biokb.ncpsb.
org/AlleRGatlas/) (48) and 4 allergy related proteins, including beta-
actin (ACTB), fatty acid-binding protein 5 (FABP5), protocadherin
11 (PCDH11X), and myomegalin (PDE4DIP) were identified.
Among the 4 allergenic-related proteins, ACTB, PCDH11X and
PDE4DIP were upregulated but FABP5 was found to be down
regulated when compared to untreated control (Table 3). Protein-
protein interaction of the identified 4 allergenic-related proteins
showed that PrP networks with ACTB via Cofilin-1 (CFL1), while
no direct interaction was observed for FABP5, PCDH11X and
PDE4DIP (Figure 3A). Finally, analysis of individual anti-PrP
antibody treatments revealed that PDE4DIP was present after
DAT with ICSM18 and POM1 treatment, however, DAT with
ICSM35 and SAF70 was not found to be associated with allergenic
related proteins (Table 4).
Treatment of MPN with 1µg of ICSM18 or ICSM35 led to the
identification of 135 proteins after LC-MS analysis when compared
with untreated cells (Table S2). However, 73 proteins wereFrontiers in Immunology | www.frontiersin.org 8identified when compared with MPN treated with 1µg of anti-
PrP antibody 3F4 antibody (Table S3). Differentially expressed
proteins (p< 0.05) were only considered with a confidence score ≥15
(Tables S2, S3). The 135 proteins (identified vs untreated control)
were assessed for allergenicity using AllergGAtlas database and 10
allergenic related proteins were identified, including vascular
endothelial growth factor receptor 1 (FLT1), peroxiredoxin-1
(PRDX1), lysophosphatidic acid receptor 2 (LPAR2), 60 kDa heat
shock protein (HSPD1), protein disulfide-isomerase A3 (PDIA3),
L-lactate dehydrogenase (LDHA), interleukin-4 (IL4),
phosphoglycerate kinase (PGK1), peroxisome proliferator-
activated receptor delta (PPARD), and beta-actin (ACTB)
(Table 5). Among the identified 10 allergenic-related proteins,
LPAR2, HSPD1, PGK1, PPARD, and ACTB were found to be
upregulated, but FLT1, PRDX1, PDIA3, LDHA, and IL4 were found
to be downregulated when compared to untreated control
(Table 5). Furthermore, allergenicity assessment of the 73
proteins (identified vs 3F4 treated control) revealed 5 allergenic-
related proteins, including LDHA, LPAR2, elongation factor 1-
alpha (EEF1A1), FLT1, and gamma actin-like protein (ACTG1)
(Table 6). Among the 5 allergenic proteins, LDHA, EEF1A1 and
FLT1 were found to be downregulated and LPAR2 as well as
ACTG1 were found to be upregulated (Table 6).
Analysis of individual direct anti-PrP antibody treatment effect
on MPN (vs no treatment) showed that FLT1, PRDX1, LPAR2,
PDIA3 and IL4 are present after ICSM18 and ICSM35 treatment,
but PGK1 and HSPD1 were found to be present after ICSM35
treatment when compared with untreated cells (Table 7). However,
analysis of individual direct anti-PrP antibody treatment effect on
MPN (vs 3F4) revealed that LDHA, LPAR2, EEF1A1, FLT1 and
ACTG1 are present after ICSM18 and ICSM35 treatment (Table 8).
Protein-protein interaction analysis of the identified 10
allergenic-related proteins revealed that FLT1, PRDX1, PDIA3,
IL4, PGK1, HSPD1, LDHA and ACTB are part of the same
interactome, however, PDIA3 and HSPD1 were observed to
interact directly with PRNP (Figure 3B). Protein-protein
interaction analysis of the 5 allergenic-related proteins (vs 3F4)
revealed that EEF1A1 and ACTG1 directly interact with each other,
whereas LDHA and FLT1 interact via other proteins (Figure S2).
Co-Culture of Anti-PrP Antibody Treated-
Microglia with Neurons Leads to Neuronal
Type 2-Like Hypersensitivity In Vitro
Initially, we measured levels of NO, IL6 and TNF-a in the
supernatants of N11 following treatment with anti-PrPTABLE 3 | Properties of the identified allergenic proteins following direct antibody treatment (DAT) of the neuroblastoma cell line.
Accession Gene Id Protein Name Anova (p) Max Fold Change Confidence Score Peptides Unique
peptides
Highest Mean Lowest Mean
Q05816 Fabp5 Fatty acid-binding
protein 5
0.017 16 260 22 3 CTL DAT
B1AZR7 Pcdh11X Protocadherin 11 0.006 11.7 60.8 9 4 DAT CTL
Q3UBP6 Actb Uncharacterized protein 0.018 12.3 802 58 3 DAT CTL
Q3UR03 Pde4dip Myomegalin (Fragment) 0.02 29.9 49.1 7 3 DAT CTLJuly 2021 | Volume 12 |The properties were identified by Progenesis Software after the LC-MS analysis.Article 639008
Adhikari et al. Anti-PrPC Antibody-Neuronal Hypersensitivityantibodies to confirm the activation status of the cells (Figure 4).
Here, we show that treatment with POM1 and POM2 as well as
ICSM18 and ICSM35 led to substantial accumulation of NO and
IL6 in the cell culture media supernatant at day 1, 2 and 3, with
exception of POM3 which led to increased synthesis of NO but
not IL6. Moreover, TNF-a release into the supernatant was
found to be marginally increased on day 1 and 3 post antibody
treatment with POM1, POM2, POM3, ICSM18 and ICSM35.
Co-culture of N2a cells with anti-PrP antibody-treated N11
cells led to the identification of 2346 proteins (only p < 0.05) after
LC-MS analysis when compared with co-culture of N2a cells
with untreated-N11 cells. Out of the 2346 proteins, only the
differentially expressed proteins were considered using
maximum fold change ≥10, at least 2 identified unique
peptides and a confidence score ≥ 40. The stringent parameters
used here led to the identification of 113 proteins (Table S4). The
113 proteins were assessed for allergenicity, and 8 proteins wereFrontiers in Immunology | www.frontiersin.org 9confirmed to be allergenic (Table 9), including IF rod domain-
containing protein (VIM), peroxiredoxin-1 (PRDX1), Legumain
(LGMN), cytoskeletal beta-actin (ACTB), V(D)J recombination-
activating protein 1 (RAG1), L-lactate dehydrogenase (LDHA),
Receptor-type tyrosine-protein phosphatase C (PTPRC), and
TIR domain-containing protein (TLR3). Among the identified
8 allergenic-related proteins, 7 (VIM, LGMN, ACTB, RAG1,
LDHA, TLR3, PTPRC) showed the highest mean for DMT when
compared with N2a cultured with untreated-N11 cells (Table 9).
Protein-protein interaction of the identified 8 allergenic-
related proteins showed that PrP interacts with ACTB via
Cofilin-1 (CFL1), while VIM, PTPRC, and LDHA directly
interacts with ACTB (node 1, 2, 3, 4 in Figure 5A). It was
previously shown that overexpression of PrPC itself activates the
NADPH oxidase (NOS) for reactive oxygen species (ROS)
production that initiates the cofilin activation and finally
induce cofilin-actin rods in hippocampal neurons (53).TABLE 4 | Identification of antibody-specific allergenic proteins following direct antibody treatment (DAT).
Gene ID Accession ICSM Antibodies SAF Antibody POM Antibody
ICSM18 CTL ICSM35 CTL SAF70 CTL POM1 CTL
Q05816 Fabp5 - - - - - - - -
B1AZR7 Pcdh11X - - - - - - - -
Q3UBP6 Actb - - - - - - - -
Q3UR03 Pde4dip √ - - - - - √ -July 2021 | Volume 12 | Article 6(√) Upregulated and (-) Downregulated.A B
FIGURE 3 | Protein-protein interaction of the identified allergenic genes following direct antibody treatment (DAT) of mouse neuroblastoma cells and mouse primary
neuron (MPN). Protein-protein interaction analysis was performed using STRING v11.0 server. The Mus Musculus database was used as the host organism for the
identification of protein interactions. (A) Protein-protein interaction of the identified allergenic genes in mouse neuroblastoma cells. Herein, interaction among the
allergenic proteins (numbered 1, 2, 3, & 4) and with PrPC (numbered 5) following direct antibody treatment. (B) Protein-protein interaction of the identified allergenic
genes in mouse primary neuron (MPN). Herein, interaction among the allergenic proteins (numbered 1, 2, 3, 4, 5, 6, 7, 8, 9 & 10) and with PrPC (numbered 0)
following direct antibody treatment, where red and yellow color indicate the downregulated and upregulated genes, respectively and green color represents the
cellular prion protein PrPC.39008
Adhikari et al. Anti-PrPC Antibody-Neuronal HypersensitivityProtein-protein interaction revealed that both RAG1 (node 6 in
Figure 5A) and TLR3 (node 5 in Figure 5A) indirectly interact
with ACTB (node 1 in Figure 5A) via PTPRC (node 3 in
Figure 5A) while PRDX1 (node 7 in Figure 5A) indirectly
interacts with ACTB via LDHA (node 4 in Figure 5A). A
study by Wagner and co-workers showed that PRDX6 was
upregulated in scrapie-infected mice and neuronal cell lines
(54). However, LGMN (node 8 in Figure 5A) did not interact
with any of the identified allergenic-related proteins as well as
with PrPC protein (node 9 in Figure 5A). Among the identifiedFrontiers in Immunology | www.frontiersin.org 10allergenic-related proteins, VIM was found to be involved in the
progression of allergic diseases via inflammasome (55, 56) and
VIM-P38MAPK complex facilitates mast cell activation via
FceRI/CCR1 activation (57). LDHA was identified as a
potential marker in allergic alveolitis, airway inflammation,
allergic encephalomyelitis, asthma disease (58–61). PRDX1 was
found as a negative regulator of inflammation (62), Th2-type
airway inflammation, and allergen-related hyperresponsiveness
(63). PTPRC was found to be associated with asthma related
phenotypes in a microarray analysis (64). LGMNwas found to beTABLE 6 | Properties of the identified allergenic proteins following direct antibody treatment (DAT) and direct microglia treatment (DMT) on the mouse primary neuron















Direct Antibody Treatment (DAT)
Q3TCI7 Ldha L-lactate dehydrogenase 15 4 126 1.31E-05 14.9 3F4 DAT
A0A571BEW5 Lpar2 Lysophosphatidic acid receptor 2 3 2 19.3 1.65E-05 32.4 DAT 3F4
Q58E64 Eef1a1 Elongation factor 1-alpha 22 2 253 0.000541 9.08 3F4 DAT
A0A0R4J0A4 Flt1 Vascular endothelial growth factor
receptor 1
4 4 15.6 0.000542 5.12 3F4 DAT
Q9QZ83 Actg1 Gamma actin-like protein 25 1 267 0.020739 2.44 DAT 3F4
Direct Microglia Treatment (DMT)
Q78NA6 Rag1 V(D)J recombination-activating protein
1
5 3 22.3 0.000645 4.79 3F4 DMT
Q546G4 Alb Serum albumin 29 26 194 0.023819 2.29 DMT 3F4
P16045 Lgals1 Galectin-1 3 3 20 0.027397 2.06 DMT 3F4
Q3UBS0 Apoe Uncharacterized protein 7 5 38.8 0.03547 2.23 3F4 DMTJuly 2021 | Volume 12 | AThe properties were identified by Progenesis Software after the LC-MS analysis.TABLE 5 | Properties of the identified allergenic proteins following direct antibody treatment (DAT) and direct microglia treatment (DMT) on the mouse primary neuron















Direct Antibody Treatment (DAT)
A0A0R4J0A4 Flt1 Vascular endothelial growth factor
receptor 1
4 4 15.6 7.59E-05 5.69 NOT DAT
B1AXW5 Prdx1 Peroxiredoxin-1 (Fragment) 8 6 60.2 9.35E-05 2.44 NOT DAT
A0A571BEW5 Lpar2 Lysophosphatidic acid receptor 2 3 2 19.3 0.000114 10.6 DAT NOT
P63038 Hspd1 60 kDa heat shock protein_
mitochondrial
48 43 479 0.008456 1.76 DAT NOT
F6Q404 Pdia3 Protein disulfide-isomerase A3
(Fragment)
6 1 34.6 0.00903 1.79 NOT DAT
Q3TCI7 Ldha L-lactate dehydrogenase 15 4 126 0.011567 3.83 NOT DAT
Q91Y50 Il4 Interleukin-4 3 1 27 0.015679 2.02 NOT DAT
S4R2M7 Pgk1 Phosphoglycerate kinase 12 1 115 0.018003 1.54 DAT NOT
A0A3B2W7W2 Ppard Peroxisome proliferator-activated
receptor delta
19 17 121 0.036966 1.43 DAT NOT
Q3UBP6 Actb Uncharacterized protein 36 4 356 0.040245 1.39 DAT NOT
Direct Microglia Treatment (DMT)
A0A0R4J0A4 Flt1 Vascular endothelial growth factor
receptor 1
4 4 15.6 8.51E-05 10.3 NOT DMT
Q3TD08 Ndrg1 Uncharacterized protein 6 6 32 0.001982 2.86 DMT NOT
Q78NA6 Rag1 V(D)J recombination-activating protein 1 5 3 22.3 0.002166 2.98 NOT DMT
Q61916 Muc5ac Mucin (Fragment) 3 1 24.4 0.013162 1.5 DMT NOT
A0A571BEW5 Lpar2 Lysophosphatidic acid receptor 2 3 2 19.3 0.013879 2.94 DMT NOT
Q3UBS0 Apoe Uncharacterized protein 7 5 38.8 0.015268 2.15 NOT DMT
Q99LX0 Park7 Protein/nucleic acid deglycase DJ-1 7 7 58.3 0.044158 1.36 NOT DMTThe properties were identified by Progenesis Software after the LC-MS analysis.rticle 639008
Adhikari et al. Anti-PrPC Antibody-Neuronal Hypersensitivityinvolved in allergic reaction by potentiating antigen processing
(65). A study by Sehra et al. showed that RAG1-deficient mice
exhibited reduced mast cell infiltration when it was used as a
chronic model of allergic inflammation (66). TLR3 activation in
an established experimental allergic asthma mice model
increased the release of proinflammatory cytokines and mucus
production which was also associated with the increased
production of interleukin 17 (IL-17A) by natural killer (NK)
cells (67).
The highest versus lowest mean of the allergenic-related
protein expression by individual antibody treatments when
compared to untreated control is shown in Table 10. Here, we
show that ICSM18, ICSM35, and SAF70 share 62.5% allergy
related proteins (5 proteins: VIM, LGMN, RAG1, LDHA, and
PTPRC). POM2 and SAF32 showed 75% effect with 6 proteins,
but the proteins were found to be different for both POM2 (VIM,
ACTB, LGMN, RAG1, LDHA, and TLR3) and SAF32 (VIM,
ACTB, LGMN, RAG1, LDHA, and PTPRC). However, the
lowest effect of antibody was observed for both POM1
(4 proteins; VIM, ACTB, RAG1, and TLR3) and POM3
(4 proteins; VIM, ACTB, LGMN, and LDHA) with 50% effect.Frontiers in Immunology | www.frontiersin.org 11Co-culture of N2a cells with anti-PrP antibody-treated N11
cells led to substantial accumulation of NO and IL6 but not
TNF-a in the cell culture media supernatant at day 3 (Figure 6).
More specifically, POM3, SAF32, SAF70 and ICSM18 led to a
substantial increase of NO in the cell culture media supernatant;
however, POM1, POM2 and ICSM35 did not show similar effect
(Figure 6A). Moreover, POM3, ICSM18 and ICSM35 but not
POM1, POM2 SAF32 and SAF70 also led to a substantial
increase of IL6 in the cell culture media supernatants
(Figure 6B). Interestingly, none of the antibodies had an effect
on TNF-a release (Figure 6C). Of note, String analysis showed
that IL6 interacts directly with 4 out of 8 allergenic-related
proteins (ACTB, RAG1, TLR3, PTPRC) and indirectly with 2
out of 8 allergenic-related proteins via ACTB (VIM, LDHA)
(data not shown).
Co-culture of untreated MPNs with ICSM18 or ICSM35-
treated N11 led to the identification of 161 proteins (p <0.05)
when compared with co-culture with MPN co-cultured with
untreated N11. Furthermore, 77 proteins (p <0.05) were
identified when compared with co-culture of MPN with 3F4-
treated N11. Out of the 161 proteins and 77 proteins, only theTABLE 8 | Identification of antibody-specific allergenic proteins following direct antibody treatment (DAT) and direct microglia treatment (DMT) on mouse primary neuron
(MPN) cells in comparison with 3F4 antibody treated cells.
Comparison with 3F4
Treatment Accession ID Gene ID ICSM18 CTL (3F4) ICSM35 CTL (3F4)
Direct Antibody Treatment
(DAT)
Q3TCI7 Ldha - √ - √
A0A571BEW5 Lpar2 √ - √ -
Q58E64 Eef1a1 - √ - √
A0A0R4J0A4 Flt1 - √ - √
Q9QZ83 Actg1 √ - √ -
Direct Microglia Treatment
(DMT)
Q78NA6 Rag1 - √ - √
Q546G4 Alb - - √ -
P16045 Lgals1 - - - -
Q3UBS0 Apoe - – - √July 2021 | Volume 12 | Arti(√) Upregulated and (-) Downregulated.TABLE 7 | Identification of antibody-specific allergenic proteins following direct antibody treatment (DAT) and direct microglia treatment (DMT) on mouse primary neuron
(MPN) cells in comparison with untreated cells.
Comparison with No Treatment (NOT)
Treatment Accession ID Gene ID ICSM18 CTL (NOT) ICSM35 CTL (NOT)
Direct Antibody Treatment
(DAT)
A0A0R4J0A4 Flt1 - √ - √
B1AXW5 Prdx1 - √ - √
A0A571BEW5 Lpar2 √ - √ -
P63038 Hspd1 - - √ -
F6Q404 Pdia3 - √ - √
Q3TCI7 Ldha - - - -
Q91Y50 Il4 - √ - √
S4R2M7 Pgk1 - - √ -
A0A3B2W7W2 Ppard - - - -
Q3UBP6 Actb - - - -
Direct Microglia Treatment
(DMT)
A0A0R4J0A4 Flt1 - √ - √
Q3TD08 Ndrg1 √ √
Q78NA6 Rag1 - √ - √
Q61916 Muc5ac - - √ -
A0A571BEW5 Lpar2 - - √ -
Q3UBS0 Apoe - √ - √
Q99LX0 Park7 - - - -(√) Upregulated and (-) Downregulated.cle 639008
Adhikari et al. Anti-PrPC Antibody-Neuronal HypersensitivityTABLE 9 | Properties of the identified allergenic proteins following direct microglia treatment (DMT) on the neuroblastoma cell line.
Accession Gene
ID










Q3TWV0 Vim IF rod domain-containing protein 0.000478 221 865 61 2 DMT Control
B1AXW5 Prdx1 Peroxiredoxin-1 (Fragment) 0.010465 10.7 280 28 3 DMT DMT
A2RTI3 Lgmn Legumain 3.27E-07 443 51.3 8 2 DMT DMT
O89054 Actb Cytoskeletal beta-actin (Fragment) 2.63E-05 28.2 201 16 2 DMT DMT
Q78NA6 Rag1 V(D)J recombination-activating protein 1 2.91E-13 13.5 95.2 16 5 DMT DMT
Q3UDU4 Ldha L-lactate dehydrogenase 7.9095E-
05
13.5 474 41 6 DMT DMT
Q3TM31 Tlr3 TIR domain-containing protein 0.043612 14.8 43.2 9 2 DMT DMT
P06800 Ptprc Receptor-type tyrosine-protein
phosphatase C
6.11E-07 12.5 41.1 6 2 DMT DMTFrontiers in Immunology | www.frontiersin.org 12 July 2021 | Volume 12 | AThe properties were identified by Progenesis Software after the LC-MS analysis.A
B
C
FIGURE 4 | Activation of microglia cells (N11) following treatment with anti-PrP antibodies. Measurement of proinflammatory cytokines following direct anti-PrP
antibody treatment of mouse microglia (N11) cell line in cell culture supernatant. Herein, fold change of NO (A), IL-6 (B) and TNF-a (C) production on day 1, 2 and 3
post-antibody treatments compared to untreated cells (day 0). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. day 0, #p < 0.05, ####p < 0.0001 compared
between day 1, 2 and 3. P values were obtained by One-way ANNOVA followed by Tukey’s multiple comparisons test analysis by GraphPad Prism 8.rticle 639008
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Frontiers in Immunology | www.frontiersin.org 13differentially expressed proteins were considered using the
p value < 0.05 and confidence score ≥15. After applying those
parameters, we found 88 proteins (vs untreated) (Table S5) and
49 proteins (vs 3F4 treated) (Table S6). The allergenicity
assessment of the 88 proteins (vs untreated) through identified
7 allergenic-related proteins, including FLT1, uncharacterized
protein (NDRG1), RAG1, mucin (MUC5AC), LPAR2,
uncharacterized protein (APOE), and protein/nucleic acid
deglycase DJ-1 (PARK7) (Table 5). Moreover, Analysis of the
49 proteins (vs 3F4 treated) identified 4 allergenic-related
proteins including, RAG1, serum albumin (ALB), galectin-1
(LGALS1) and APOE (Table 6). Protein-protein interaction
analysis of the 7 allergenic-related proteins (vs untreated)
revealed that PRNP directly interacts with APOE and PARK7
while FLT1, RAG1, LPAR2, NDRG1 are part of the same
interactome (Figure 5B). Protein-protein interaction among
the identified 4 allergenic-related proteins (vs 3F4) showed
direct interaction between PRNP, APOE and ALB (Figure S3).
The individual effect of anti-PrP antibody treatment on MPN
when compared with untreated control is shown in Table 7. Herein,
NDRG1was upregulated while FLT1, RAG1 and APOE were
downregulated after ICSM18 treatment (Table 7). Moreover,
ICSM35 treatment upregulated NDRG1, MUC5AC and LPAR2
and downregulated FLT1, RAG1 and APOE (Table 7).
The individual effect of anti-PrP antibody treatment on MPN
when compared with 3F4 treated control is shown in Table 8. No
protein upregulation occurred after ICSM18 treatment, however
downregulation of RAG1 was observed. ICSM 35 led to
upregulation of ALB while both RAG1 and APOE were
downregulated (Table 8).
In order to verify whether the allergenic-related proteins
identified in MPN following DMT were specifically stimulated in
neurons (and not in both neurons and microglia), we compared the
proteome of the anti-PrP antibody-treated microglia without co-
culture with neurons and found that anti-PrP antibody-treated
microglia only did not display any common allergy-related proteins
with DMT (Table S7) indicating that our identified allergy-related
proteins were specifically activated in neurons.
Co-culture of MPN with ICSM18 or ICSM35 anti-PrP
antibody-treated N11 cells led to substantial accumulation of
NO and IL6 (Figures 7A, B) but not TNF-a (Figure 7C) in the
cell culture media supernatant at day 3 when compared with
both untreated and 3F4-treated cells. String analysis showed that
IL6 interacts directly with 5 out of 7 allergenic-related proteins vs
untreated (APOE, RAG1, MUC5AC, FLT1, PARK7) and directly
with 4 out of 4 allergenic-related proteins vs 3F4-treated control
(RAG1, ALB, LGALS1, APOE) (data not shown).Contactless Co-Culture of Anti-PrP
Antibody Treated-Microglia with Neurons
Leads to Neuronal Type 2-Like
Hypersensitivity In Vitro
Contactless co-culture of anti-PrP antibody treated microglia
N11 and N2a cells was designed to verify whether the allergenicA
B
FIGURE 5 | Protein-protein interaction analysis among the identified
allergenic genes following direct microglial treatment (DMT) with anti-PrP
antibodies in cell line and mouse primary neuron. The analysis was
performed using STRING v11.0 server. The Mus Musculus database was
used as the host organism for characterising the protein interactions.
(A) Protein-protein interaction among the identified 8 allergenic genes
following direct microglial treatment (DMT) with anti-PrP antibodies in
mouse neuroblastoma cell line. Herein, interaction among the allergenic
proteins and with PrPC where the numbered purple circles (numbered 1, 2,
3, 4, 5, 6) and numbered red circle refer to allergenic-related proteins
identified following DMT and shown here to be part of the same
interactome. The red circle (numbered 7) was shown to be downregulated
and the orange circle (numbered 8) is not part of the interactome with other
allergenic-related proteins. Finally, the green circle (numbered 9) represents
the prion protein, PrPC. (B) Protein-protein interaction among the 7
identified allergenic genes following direct microglial treatment (DMT) with
anti-PrP antibodies in mouse primary neuron (MPN). Herein, Interaction
among the allergenic proteins (numbered 1, 2, 3, 4, 5, 6 & 7) and with PrPC
(numbered 0) following direct microglia treatment where red and yellow
color indicate the downregulated and upregulated genes, respectively and
green color represents the cellular prion protein PrPC.July 2021 | Volume 12 | Article 639008
Adhikari et al. Anti-PrPC Antibody-Neuronal Hypersensitivityeffects caused by DMT were due to a direct cognate interaction of
N2a and N11 or via indirect release of microglial factors which in
turn might have led to hypersensitivity. N11 cells were initially
treated with anti-PrP antibodies, including ICSM18, ICSM35,
POM1, POM2, POM3, SAF32 or SAF70 on cell culture inserts
before placing the inserts containing antibody-treated microglia
on cell culture plate containing untreated N2a cells (IMT). IMT
resulted in an initial dataset of 292 proteins (p < 0.05) after LC-
MS analysis. Differentially expressed proteins (p < 0.05) wereFrontiers in Immunology | www.frontiersin.org 14considered with a maximum fold change ≥10 and at least 2
identified unique peptides and a confidence score ≥ 10 and
identified a total of 11 proteins (Table S8). Out of the 11
proteins, AllergGAtlas database only identified Integrin beta-4
(ITGB4) (upregulated, p=0.034, maximum fold change 45,
confidence score 33.6, peptide 6, unique peptide 3) as being
allergenic. The protein-protein interaction analysis showed that
ITGB4 indirectly interacts with PRNP via ITGB6 and NCAM 1
(Figure S4).TABLE 10 | Identification of antibody-specific allergenic proteins following direct microglia treatment (DMT).
Accession ID Gene ID ICSM Antibodies POM Antibodies SAF Antibodies
ICSM18 CTL ICSM35 CTL POM1 CTL POM2 CTL POM3 CTL SAF32 CTL SAF70 CTL
Q3TWV0 Vim √ - √ - √ - √ - √ - √ - √ -
B1AXW5 Prdx1 - √ - √ - - - √ - - - √ - √
A2RTI3 Lgmn √ - √ - - - √ - √ - √ - √ -
O89054 Actb - - - - √ - √ - √ - √ - - -
Q78NA6 Rag1 √ - √ - √ - √ - - - √ - √ -
Q3UDU4 Ldha √ - √ - - - √ - √ - √ - √ -
Q3TM31 Tlr3 - - - - √ - √ - - - - - - -
P06800 Ptprc √ - √ - - - - - - - √ - √ -July 2021 | Volume 12 | Article 63(√) Upregulated and (-) Downregulated.A B C
FIGURE 6 | Production of proinflammatory cytokines following direct microglial treatment (DMT) with anti-PrP antibody treatment of mouse neuroblastoma cell line.
Herein, fold change of NO (A), IL-6 (B) and TNF-a (C) production in N2a following DMT. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. no treatment (NoT).
P values were obtained by One-way ANNOVA followed by Tukey’s multiple comparisons test analysis by GraphPad Prism 8.A B C
FIGURE 7 | Production of proinflammatory cytokines following direct microglial treatment (DMT) with anti-PrP antibody treatment of mouse primary neuron (MPN).
Herein, fold change of NO (A), IL-6 (B) and TNF-a (C) production in MPN following DMT. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. no treatment (NoT).
##p < 0.01, ###p < 0.001, ####p < 0.0001 vs. 3F4 antibody treatment. P values were obtained by One-way ANNOVA followed by Tukey’s multiple comparisons test
analysis by GraphPad Prism 8.9008
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Leads to Differential Expression of FcϵR1a
The high affinity IgE receptor (FcϵRI) is a tetrameric receptor
complex which is composed of one a-subunit (FcϵRIa), one b-
subunit (FcϵRIb) (68) and two g-subunits (FcϵRIg) (69–71).
During a classic IgE-mediated allergic immune response,
FcϵRIa directly binds IgE with high affinity, while FcϵRIb and
FcϵRIg are responsible for mediating intracellular signals (68,
71–73). Furthermore, binding of the IgG receptors FcgRII and
FcgRIII receptors to the IgE-immune complexes contribute to
the induction of cell activation (74). Ujike and colleagues also
showed that FcgRII and FcgRIII not only modulates IgG-
mediated hypersensitivity responses but also acts as an effective
regulators of IgE-mediated reactions (75). The IgG/FcgR
pathway was shown to induce an anaphylactic reaction
following activation of basophils, macrophages, and
neutrophils (76–78). The IgG FcgR and IgE FcϵRI share a
common g subunit and comparable signaling pathways.
Falanga and colleagues showed that the Lyn and Fyn kinases
were activated after FcgR stimulation (79). Of importance, the
authors demonstrated that both Fyn and Lyn regulate FcgR-
mediated degranulation and cytokine and chemokine and
histamine release was regulated by Fyn and Lyn. Moreover,
clustering of PrPC was shown to activate Fyn kinase as both
localize lipid rafts (14). Finally, PrPC-dependent signal
transduction revealed that PrPC coupled with Fyn kinase
following anti-PrP antibody-mediated cross-linking (15).
Herein, we wanted to verify whether cross-linking neuronal/
microglial PrPC with anti-PrP antibody alters the expression of
FcϵRI. Western blot analysis displayed a ~50 kDa and ~25 kDa
band corresponding to FcϵRIa and FcϵRIg subunits respectively,
in MPN after DAT with ICSM35 (Figure 8A). DAT of MPN
with ICSM18, 3F4 and untreated cells did not display any band
(Figure 8A). However, Western blotting and densitometry
analysis following DMT with ICSM18 and ICSM35 of MPN
displayed substantially higher ~50 kDa and ~25 kDa band
intensity corresponding to FcϵRIa and FcϵRIg respectively
when compared with DMT with 3F4 and untreated cells
(Figures 8A, B). Similarly, Western blotting and densitometry
analysis following DMT with ICSM18 and ICSM35 of co-
cultured N2a with ICSM18 or ICSM35-treated N11 displayed
higher ~50 kDa, ~35 kDa and ~25 kDa band intensity
corresponding to FcϵRIa, FcϵRIb and FcϵRIg respectively
when compared with untreated cells (Figures 8C, E). In
contrast, DAT with ICSM35 of N2a displayed higher ~50
kDa, ~35 kDa and ~25 kDa band intensity corresponding to
FcϵRIa, FcϵRIb and FcϵRIg respectively when compared with
ICSM18 treated and untreated cells (Figures 8C, D).
In order to identify the protein interactors with FcϵRIa
following DAT with ICSM35 of MPN, the corresponding gel
bands were trypsin digested prior to LC-MS analysis. Here, 12
proteins were identified, of which peroxisome proliferator-
activated receptor delta (PPARD) was recognized as an
allergenic-related protein (Table S9). Protein-protein
interaction of PPARD and FcϵRIa showed that they are
located in the same protein network and interacting throughFrontiers in Immunology | www.frontiersin.org 15two signaling molecules, namely CREB-binding protein
(CREBBP) and Tyrosine-protein kinase Lyn (LYN)
(Figure 8F). Further protein network analysis showed that
PPARD direct ly interacts with several al lergy and
inflammation proteins such as fatty acid-binding protein
(FABP5) (80, 81), retinoic acid receptor RXR-alpha (RXRA)
(82), pyruvate dehydrogenase E1 component (PDHX) (83),
catenin beta-1 (CTNNB1) (84–86), mothers against
decapentaplegic homolog 4 (SMAD4) (87, 88) and retinoic
acid receptor RXR-beta (RXRB) (89) (Figure 8G) confirming
its association with allergy. This interaction analysis also revealed
that PRNP interacts with PPARD and FceR1a via a network of
other proteins as part of the same interactome (Figure 8H). As
summarized in Figure 9, most of the proteins associated with all
treatments with anti-PrP antibodies have their primary location
in the plasma membrane and cytoplasm, whereas only 3 were
seen in the nucleus, 2 in the endoplasmic reticulum, 1 in the
Golgi, 1 in the mitochondria, and 1 in the lysosome. NDRG1,
PARK7 and VIM proteins have a ubiquitous cellular location.
Proteins involved in negative regulation of reactive oxygen
species, of neuronal apoptosis and development of neuronal
projections were highly represented.DISCUSSION
Hypersensitivity reactions are triggered by the immune
response. Little is known about the so-called IgG-mediated
neuronal hypersensitivity, however, a body of new emerging
studies suggest that hypersensitivity is an important feature in
response to IgG immunotherapy or disease-associated auto-
antibodies (90–92). Fcg receptors (FcgRs) are known to
mediate protective immune functions via binding of IgG
molecules to the Fc domain in addition to modulating the
adaptive immune response. FcgRs have been implicated in
hypersensitivity reactions; for instance, Fcg-chain-deficient
mice were protected against a number of autoimmune
disorders [reviewed in (93)], suggesting an important role
for FcgRI in hypersensitivity reactions. Furthermore,
functional polymorphism in FCgRs genes was shown to play
an important role in the pathogenesis of allergy (94). A
number of in vitro and in vivo studies have demonstrated
the presence of FcgRs in neurons. Previous reports implicated
IgG in inducing a neuronal hypersensitivity reaction (91). Of
importance, Fuller et al. highlighted the importance of
increased expression and ligation of FcgRs in the CNS as a
result of administration of therapeutic antibodies or by
endogenous IgG which resulted in vascular damage and
exacerbation of neurodegeneration (95). Furthermore,
experimental treatment with anti-PrP antibodies directed
against PrPC led to neuronal apoptosis based on microscopic
assessments (23, 24, 26). Upon further analysis, some
of these studies also revealed that anti-PrP antibodies
induced activation of allergenic-related proteins identified
by the AllerGAtlas database (21, 27, 28). We therefore
sought molecular confirmation of a neuronal type 2-likeJuly 2021 | Volume 12 | Article 639008
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treatment of neurons and microglia in vitro. Initially, we
performed in silico analysis to predict the most antigenic
epitopes from the huPrP 3D structure and to verify whether
some of the predicted motifs overlap with those recognized by
the reported ‘neurotoxic’ anti-PrP antibodies such as ICSM
and POM antibodies (40, 43). The in-silico analysis revealed a
set of antigenic B cell linear epitopes located on the flexible tailFrontiers in Immunology | www.frontiersin.org 16(FT) region. Interestingly, epitopes L2 and L9/L10 were
mapped to the ‘neurotoxic’ antibodies ICSM35 (26, 40) and
POM3 (23, 24, 27, 43). We also confirmed that L2, L9 and L10
were toxic following assessment with the ToxinPred server
(50) by quantitative matrix based method (QM method). The
in-silico analysis also revealed a set of antigenic B cell linear
epitopes located on the globular (GD) region of which L4 was







FIGURE 8 | Differential expression of FceR receptors following anti-PrP antibody treatment to mouse primary neuron cells and mouse neuroblastoma cell line.
Western blotting of (A) direct antibody treatment (DAT) and direct microglia treatment (DMT) of mouse primary neuron cells (B) densitometry analysis of (A). (C) DAT
and DMT of mouse neuroblastoma cells (D, E) densitometry analysis of (F). (F) protein-protein interaction of PPARD with FceR1a (G) Illustration of protein
interactome with PPARD (H) Illustration of protein-protein interactions between PPARD, FceR1a and PrPC.July 2021 | Volume 12 | Article 639008
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L4 as being toxic. While performing in-silico analysis to assess
antigenicity and toxicity of epitopes located on the huPrP 3D
structure, we also noticed that some antigenic epitopes were
predicted to be allergenic by AllergenFP (51) and AllerTop
(52) allergenicity prediction servers. A total of 7 B cell linear
epitopes were identified as allergenic. Of interest, L4 was
mapped to the neurotoxic antibodies POM1 and ICSM18
and L2 was mapped to ICSM35 and POM3 while L9 and
L10 were both mapped to POM2. POM1, a similar antibody to
ICSM18 and mapped to the L4 epitope was previously shown
to induce neurotoxicity via calpain (27). Our LC-MS data also
shows that calpain 1 is activated by ICSM18 treatment, but on
the contrary led to inhibition of calpain 3 (data not shown),
probably via negative feedback following cross-linking PrPC.
In addition to its newly characterized role in antibody-induced
neuronal apoptosis, calpains have a well-established role in
allergy (96–98). For instance, a study by Wu et al. showed that
calpain 1 contributes to mast cell degranulation (96).
Furthermore, inhibition of mGluRs, known to regulate
histamine (34), abolished the anti-PrP antibody toxic effects
(28). Taken together and in addition to the allergenic-related
proteins associated with ICSM35 treatment reported by
Tayebi and colleagues (21), this provides sufficient evidence
to investigate the allergenic pathways potentially induced by
treatment with anti-PrP antibodies which we refer to as “IgG-
Mediated Neuronal Hypersensitivity”. To that end, we treated
mouse primary neurons (MPN), mouse neuroblastoma (N2a)
and microglia (N11) cell lines with anti-PrP antibodies then
assessed the neuronal allergenic proteome following mass
spectrometry analysis as well as expression of neuronal
FceR1a. ACTB was found to be activated in both MPN andFrontiers in Immunology | www.frontiersin.org 17N2a shown to interact with PrPC via cofilin 1. Walsh and co-
workers demonstrated that overexpression of PrPC activates
the NADPH oxidase (NOS) for reactive oxygen species (ROS)
production which initiates cofilin activation and finally induce
cofilin-actin rods in hippocampal neurons (53). Among the 10
allergenic-related protein identified following DAT of MPN,
FLT1 was found to be directly interacting with IL4 in protein-
protein interaction analysis. FLT1 was previously shown to be
highly expressed in asthmatic patients (99), associated with
allergic inflammation as an inducer that increases the allergic
sensitization and also played a significant role in Th2 type
inflammatory responses (100). IL4 identified following DAT
of MPN directly interacting with both HSPD1 and ACTB. IL4
is a cytokine that plays a crucial role in the progression or
pathogenesis of allergic diseases since it has a key role in the
development of helper T-cell and the production of IgE (101–
106). Shi and colleagues characterised the positive role of IL-4
in airway responsiveness in patients with allergic bronchial
asthma (103). Further, Ryan and co-workers confirmed the
inhibitory role of IL-4 on mouse bone marrow and fetal liver-
derived mast cell FceRI expression through a STAT6
transcription factor-dependent mechanism (107). A study by
Niggemann et al. showed that IL-4 increases histamine release
from mast cells and peripheral blood basophils in both in vitro
and in vivo study where IL-4 plays priming effects on
histamine release (108). In another study on IL-4 primed
human cultured mast cells, enhanced IL-13 production was
observed by cross-linking of FceRI (109). Both IL-10 and IL-4
were detected in CSF of patients with Creutzfeldt-Jakob
disease (CJD) (110).
HSPD1has been found to be involved in the alveolarmacrophages
immune functions in relation to allergic asthma (111).FIGURE 9 | Cellular and subcellular localisation of allergenic-related proteins. Allergenic related proteins activated following direct anti-PrP antibody and microglia
treatments of neuroblastoma cell line and mouse primary neurons are grouped according to cellular location.July 2021 | Volume 12 | Article 639008
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mediated immune responses through the suppression of tumour
necrosis factora (TNF-a) (112).HSPD1was found tobe associated
with PrPC as a major interactor (113, 114).
PDIA3 identified following from DAT of MPN was found to
be directly interacting with PRDX1 (found in both DAT of MPN
and DMT of neuroblastoma cells), ACTB (found in DAT of
MPN and both in DAT and DMT of neuroblastoma cells), and
HSPD1. Recently, Krajewski and co-workers showed that protein
disulfide isomerase catalytic activity plays an important role in
the regulation of mast cell activation (115). They also showed
that the inhibition of protein disulfide isomerase activity via pre-
treatment of mast cells with curcumin or other protein disulfide
isomerase inhibitor such as PACMA-31 are able to supress the
IgE mediated activation and various cytokines secretion (115).
Inouue et al. showed that PRDX1 protects against allergen-
related hyperresponsiveness and Th2-type airway inflammation
and involved in the inhibition of allergen-specific T-cell
proliferation through immunological synapse (63). PPARD
identified following DAT of MPN was found to be interacting
with FABP5 (found in DAT of neuroblastoma cells). Expression
of PRAR is altered during inflammatory responses such as airway
inflammation, indicating that PPAR is involved in the
pathogenesis of allergic asthma (116–120). PPARbeta/delta was
found to be act modulators in many mediators of inflammation
(118, 121–124) while the activation of PPARbeta/delta also play
an important roles in inflammation by inducing expression of
transforming growth factor-b1 (TGF-b1) (125) and sIL-1ra
(126). Several studies have confirmed the inhibitory effect of
PPAR agonists in immune and inflammatory responses,
especially in the central nervous system inflammation and
demyelination in experimental autoimmune encephalomyelitis
(127–130). Kanakasabai and co-workers showed that PPARD
agonist (GW501516 and L165041) ameliorates the experimental
autoimmune encephalomyelitis in C57BL/6 mice by inhibiting T
helper type 1 (Th1) and Th17 responses (131). The inhibitory
effect of PPARD agonist was also found to be associated with an
increase of cytokine IL-4 and IL-10 expression and decreased IL-
12 and IL-23 expression in the CNS confirming the modulatory
effect of PPARD agonist in experimental autoimmune
encephalomyelitis (131).
Due to the important role played by microglia in the
exacerbation of neuropathology in the prion and other related
disorders, we sought to verify whether co-culture of N2a/MPN
with anti-PrP antibody-treated N11 (DMT) leads to a neuronal
hypersensitivity reaction.
A study by Toda et al. revealed that VIM-P38MAPK complex
facilitates mast cell activation via FcϵRI/CCR1 activation (57).
Amongst the DMT associated allergenic-related proteins, LDHA
was found to interact with PRDX1. Interestingly, PRDX6, a
protein that directly networks with our downregulated PRDX1,
was shown to be upregulated in scrapie-infected mice and
neuronal cell lines and controls expression of PrPC and PrPSc
in neuronal cells (54). PTPRC previously shown to be
upregulated in brain of mice following infection of prion (132),
is associated with asthma related phenotypes (64) and its ligationFrontiers in Immunology | www.frontiersin.org 18enhances the frequency of constitutive apoptosis in human
eosinophils (133). RAG1 plays an important regulatory role in
the reorganization and recombination of T cell receptor (TCR)
and immunoglobulin (Ig) genes (134). A study by Sehra et al.
showed that Rag1-deficient mice exhibited reduced mast cell
infiltration when it was used as a chronic model of allergic
inflammation (66). Of importance, RAG1 was a common protein
identified in DMT with N2a and MPN (vs untreated and 3F4
treated) and was shown to directly interact with IL6 in String
analysis. Further, we show that IL-6 was substantially increased
in all DMTs, including co-cultures N11 with N2a (vs untreated)
and N11 with MPN (vs untreated and vs 3F4 treated). Previous
studies demonstrated the effect of treatment of toxic PrP peptide
in inducing microglia activation and cytokine release (135).
Garcao and colleagues showed that treatment of microglia led
to increased IL-6 secretion, responsible for increased neuronal
death (136, 137). Interestingly, none of the antibody treatment
following DMT were able to affect the production and increase of
TNF-a. Previous studies have demonstrated that IL6 antagonizes
the action of TNF-a (138, 139).
Another allergenic protein identified following DMT is TLR3
that directly interact with PTPRC. TLR3 is a membrane protein
which act as a pathogen recognition receptor and is expressed in
the CNS and other cell types (140). TLR3 activation by poly
(inosinic-cytidylic) acid in an established experimental allergic
asthma mice model increased the release of proinflammatory
cytokines and mucus production which was also associated with
increased production of IL-17A by NK cells (67). Starkhammar
and colleagues showed that combined stimulation of TLR3 and
TLR4 causes airway hyperresponsiveness which is increased
during an ongoing allergic inflammation (141). ALB was
identified following DMT of MPN when compared with 3F4
treated cells. ALB is a multifunctional protein which is broadly
distributed in the body and is used as a sensitizing mediator in
various immunological pathways and also acts as a carrier of
several drugs (142). The involvement of ALB in allergy has been
described in several studies (143–146).
Analysis of individual anti-PrP antibody treatment identified
that the highest allergenic effect, as assessed by the number of
allergenic-related proteins, was associated with the GD and FT
targeting antibodies ICSM18/SAF70 and ICSM35 which shared 5
common proteins. ICSM18 and 35 were produced in PrP-null
mice against truncated hPrP91-231 while SAF70 was raised in
hamsters using SAF preparation. However, both ICSM18 and
SAF70 bind to a similar epitope on the GD but ICSM35 epitope
is located on the FT domain. ICSM35 and SAF70 are of the same
Ig isotype (IgG2b). It remains a challenge to pinpoint which of
these antibody characteristics led to activation of the common
proteins, however, there is strong indication that inherent
antibody properties (e.g. epitope; isotype etc.) trigger similar
allergenic pathways. POM2 and SAF32, two antibodies that bind
to an epitope on the octa-repeat activated 6 proteins separately
where 5 proteins were common and the protein TLR3 and
PTPRC was found to be activated by POM2 and SAF32,
respectively. SAF32, similar to SAF70 was raised in hamsters
using SAF preparation and is an IgG2b, while POM2 was raisedJuly 2021 | Volume 12 | Article 639008
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this case, the common octa-repeat epitope appears to be playing
a key role in triggering similar allergenic pathways by these 2
antibodies, however, all molecular aspects should also be
considered, including antibody affinity for instance. It is
noteworthy that among the 5 common proteins shared by
POM2 and SAF32, 4 proteins were also common with
ICSM18, ICSM35 and SAF70 treatments, possibly reflecting
the involvement of several antibody properties. Finally, POM1
and POM3, raised in PrP-null mice against full-length mPrP23-
231 and of IgG1 isotype with binding motifs located on GD and
FT domains respectively activated only 4 proteins with very little
commonality with the other antibody treatments.
Differential expression of FceR1a was observed following
DAT and DMT with ICSM35 antibody treatment of MPN and
mouse neuroblastoma cells. However, FceR1a overexpression
was only observed following DAT of MPN with ICSM35 but
not ICSM18, suggesting that ICSM35 binding to PrPC FT
domain stimulates FceR1 probably via binding to FcgR. Co-
localisation of PPARD with FceR1 following treatment with
ICSM35 further confirms the allergenic phenomenon induced
by the anti-PrP antibody treatment. A recent study by Moon and
co-workers have shown that a PPARg agonist (troglitazone) is
able to weaken PrP−mediated neurotoxicity in primary neuronal
cells via PPARg signal activation and autophagy flux
inhibition (147).
Antibody-mediated therapy for prions attracted intense
debate and controversy as some of the reported were
contradictory partly because these relied on a somewhat
superficial assessment using microscopy and also due to the
failure of investigating the fine molecular events caused by cross-
lining PrPC with anti-PrP antibodies. Luckily, this controversy
related to prion antibody treatment did not lead to fatalities in
humans affected with CJD. However, Alzheimer’s disease trials
have led the death of individuals administered with therapeutic
antibodies. This study led to a unique discovery showing that
anti-PrP antibodies led to neuronal allergenicity via different
pathways but also highlights the key role played by microglia in
causing the allergenic reaction. This study also emphasizes the
need to include a screening ‘allergenicity’ step during
development of therapeutic antibodies to avoid potential
side-effects.Frontiers in Immunology | www.frontiersin.org 19DATA AVAILABILITY STATEMENT
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